1. Pentoxifylline in patients with ulcerative colitis treated with mesalamine by modulation of IL-6/STAT3, ZO-1, and S1P pathways: a randomized controlled double-blinded study.
- Author
-
Bahaa MM, Hegazy SK, Maher MM, Bahgat MM, and El-Haggar SM
- Subjects
- Humans, Double-Blind Method, Male, Female, Adult, Middle Aged, Lysophospholipids metabolism, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Signal Transduction drug effects, Colitis, Ulcerative drug therapy, Colitis, Ulcerative metabolism, STAT3 Transcription Factor metabolism, Mesalamine pharmacology, Mesalamine administration & dosage, Interleukin-6 metabolism, Pentoxifylline pharmacology, Pentoxifylline administration & dosage, Zonula Occludens-1 Protein metabolism
- Abstract
Background: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) that lasts a long time and has a variety of causes., Aim: The primary aim of this study was to evaluate pentoxifylline's (PTX) essential function in patients with UC., Methods: Fifty-two mild to moderate UC patients who matched the eligibility requirements participated in this clinical study. One gram of mesalamine (t.i.d.) and a placebo were administered to the mesalamine group (n = 26) for a duration of 24 weeks. Mesalamine 1 g t.i.d. and PTX 400 mg two times daily were administered to the PTX group (n = 26) for 24 weeks. A gastroenterologist investigated patients at the start and 6 months after the medication was given to assess disease activity index (DAI) and numeric pain rating scale (NRS). Also, interleukin-6 (IL-6), sphingosine 1 phosphate (S1P), tumor necrosis factor-alpha (TNF-α), and fecal myeloperoxidase (MPO) were measured before and after therapy. Zonula occuldin-1 (ZO-1) and signal transducer and activator of transcription factor-3 (STAT-3) expression was assessed before and after therapy as well as histological assessment. Short Form 36 Health Survey (SF-36), was assessed for each patient before and after 6 months of treatment., Results: The PTX group showed statistically lower levels of serum SIP, TNF-α, IL-6, faecal MPO, gene expression of STAT-3, and a significant increase of ZO-1 in comparison with the mesalamine group. DAI and NRS significantly decreased whereas SF-36 significantly increased in the PTX group., Conclusion: PTX could alleviate inflammation in patients with UC, so it might be promising adjunctive for patients with UC., Trial Registration Identifier: NCT05558761., (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2024
- Full Text
- View/download PDF